NBTX

Business Context and Reporting Period

Company: Nanobiotix S.A.
Reporting Period: Six months ended June 30, 2025
Filing Type: Form 6-K (Interim Financial Report)
Business Overview: Nanobiotix is a late-stage clinical biotechnology company developing nanophysics-based therapies for cancer. Its primary focus is the advancement of JNJ-1900 (NBTXR3), a radioenhancer, in collaboration with Janssen Pharmaceutica NV (Johnson & Johnson). The company also maintains the Curadigm nanoprimer and OOcuity neurological disease platforms.

Key Financial Metrics

Revenue Composition (2025): Revenue was driven by a one-off €21.2 million positive adjustment from a contract modification with Janssen, €0.4 million in services, and €3.4 million in sales of clinical supplies.

Material Changes vs. Prior Period

• Revenue Surge: Total revenue increased 303% year-over-year, primarily due to a €21.2 million cumulative catch-up revenue recognition resulting from a March 2025 amendment to the Janssen License Agreement. This amendment increased the remaining transaction price of the global license agreement.
• Operating Profitability: The company shifted from an operating loss of €23.7 million in H1 2024 to an operating income of €0.8 million in H1 2025.
• Expense Reduction: R&D expenses decreased by €7.5 million (to €14.5 million) due to the transfer of sponsorship and funding obligations for the Phase 3 NANORAY-312 trial to Janssen. SG&A expenses increased slightly by €0.5 million (to €11.3 million) due to payroll costs related to stock options.
• Cash Burn: Net cash used in operating activities increased to €17.4 million from €5.8 million, largely due to lower cash inflows from Janssen in H1 2025 compared to the €18.6 million milestone payment received in H1 2024.

Guidance, Outlook, Risks, and Unusual Items

Outlook and Liquidity

Management estimates current cash reserves (€28.8 million) are sufficient to finance activities into mid-2026. However, the company explicitly states that current funds will not be sufficient to cover operating needs for the next 12 months. An additional liquidity requirement of €8 to €10 million is estimated for the next 12 months. The company is in active discussions regarding non-dilutive financing to extend its cash runway.

Going Concern Uncertainty

The filing discloses a material uncertainty regarding the company's ability to continue as a going concern due to the need for additional financing. If funding is not secured, the company may need to curtail or discontinue research programs.

Key Risks

• Financing Risk: Inability to raise necessary capital in a challenging biotech financing environment.
• Development Risk: Reliance on Janssen for the development and commercialization of JNJ-1900 (NBTXR3), including the success of the NANORAY-312 Phase 3 trial and the new CONVERGE Phase 2 trial in lung cancer.
• Regulatory Risk: Delays in clinical trial completion or regulatory approvals.

Unusual Items

The financial results are significantly impacted by the accounting treatment of the Janssen contract modification, which generated a non-recurring revenue boost and reduced future funding obligations for the pivotal Phase 3 trial.

Investor Verification Checklist

• Financing Status: Verify the progress of discussions for the required €8–10 million in additional liquidity and the timeline for securing non-dilutive funding.
• Cash Runway: Confirm the specific date by which current cash reserves are projected to be depleted (stated as mid-2026) and the assumptions behind this projection.
• Janssen Trial Progress: Monitor enrollment and data readout timelines for the NANORAY-312 (Head & Neck) and CONVERGE (Lung) trials, as these drive future milestone payments.
• Debt Obligations: Review the structure of the EIB loan (€43.5 million carrying value), which includes variable royalty-based interest payments contingent on future sales.
• Revenue Sustainability: Assess the sustainability of revenue streams post the one-time €21.2 million contract modification adjustment.